Vaccine Info

Japanese Encephalitis Virus Vaccines 2023

Authored by
Last reviewed
January 12, 2023

Japanese Encephalitis Virus 2023

Japanese Encephalitis Virus (JEV) is a flavivirus that is the leading cause of viral encephalitis in many countries of Asia, with an estimated 68,000 clinical cases every year. There is no cure for JEV.

As of January 12, 2023, safe and effective vaccines are available to prevent diseases related to JEV infections.

Japanese Encephalitis Virus Vaccines

JEV vaccination should be considered for travelers to endemic areas, says the U.S Centers for Disease Control and Prevention (CDC). However, JEV vaccines are not recommended for travelers with low-risk itineraries, such as shorter-term travel limited to urban areas or outside of a well-defined JE virus transmission season.

JENVAC is an inactivated vero cell-derived vaccine prepared from an Indian Kolar strain of the Japanese encephalitis virus.

Ixiaro is an inactivated, adsorbed Vero cell culture-derived vaccine. It is prepared by propagating JEV strain SA14-14-2 in Vero cells. Multiple viral harvests are pooled, clarified, and concentrated. The virus suspension is treated with protamine sulfate to remove contaminating DNA and proteins. This vaccine was approved in March 2009 for use in people aged 17 years and older and in May 2013 for use in children two months through 16 years of age.

Studies have shown that severe reactions to the JE vaccine are infrequent. However, as with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injuries, or death.

Japanese Encephalitis Virus Vaccine Candidates

Tiba Biotech is a preclinical-stage biopharmaceutical company developing next-generation RNA vaccines targeting JEV.

Japanese Encephalitis Virus Vaccine News 2023

January 12, 2023 - Next-Gen RNA Vaccine Technology Focuses on Disease X - Japanese Encephalitis Virus RNA vaccine development partnership.

Japanese Encephalitis Overview

Japanese encephalitis is rare, but the case-fatality rate among those with encephalitis can be high. Permanent neurologic or psychiatric sequelae can occur in 30%–50% of those with encephalitis. In addition, a person with encephalitis can experience fever, neck stiffness, seizures, and coma says the CDC.

Japanese Encephalitis vaccine content is sourced from the World Health Organization, the US Centers for Disease Control and Prevention,, and news published by Precision Vaccinations.

Clinical Trials

No clinical trials found